医药代表篡改检测报告骗保被判刑；中国医药原总经理助理李欣被查

Policy Developments - The National Medical Products Administration (NMPA) has expanded the scope of export certificates for pharmaceuticals, allowing companies to apply for export certificates for drugs produced under GMP, regardless of whether they are approved for sale in China [2] - The validity period for the "Drug Export Sales Certificate" has been extended from 2 years to 3 years, aligning it with the "Export Certificate for EU Raw Materials" [2] - The maximum processing time for export certificates has been set at 20 working days, excluding the time required for technical reviews and on-site inspections [2] Drug and Device Approvals - Heng Rui Medicine has received clinical trial approval notices for multiple drugs, including SHR-9839 and SHR-A2009, and will soon commence clinical trials [4] - Renfu Medicine's application for the marketing authorization of Dexmethylphenidate Capsules has been accepted, targeting ADHD treatment, marking a significant step as no similar products are currently available in China [5] - Baile Tianheng's innovative EGFR×HER3 dual-target ADC drug, iza-bren, has had its marketing application accepted, being the first of its kind to enter Phase III clinical trials [6] Capital Markets - Eli Lilly has become the first healthcare company to reach a market capitalization of $1 trillion, with its stock price increasing by 38% this year, driven by investor optimism regarding its weight-loss drug [8] - Changshan Pharmaceutical's controlling shareholder plans to transfer 5% of its shares to Element Fund at a price of 46.25 yuan per share, totaling 2.1275 billion yuan [9][10] Industry Events - A medical representative was sentenced to eight months in prison for fraudulently altering gene test reports to defraud health insurance, highlighting the increasing scrutiny and regulatory measures in the pharmaceutical industry [12] - Heng Rui Medicine has signed a partnership agreement with the Hong Kong Greater China Cancer Foundation to provide innovative therapies for breast cancer patients in Hong Kong [13] - Baicheng Medicine has entered into an exclusive licensing agreement with Zhongshen Innovation for the innovative drug BIOS-0629 in the Greater China region, with milestone payments of 300 million yuan [14] Public Opinion Alerts - Li Xin, former member of the Party Committee and assistant general manager of China Pharmaceutical Health Industry Co., is under investigation for serious violations of discipline and law [16]